News For THLD From The Last 14 Days Check below for free stories on THLD the last two weeks.
There are 6 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 6, 2012
|
| 12:15 EDT |  | THLD |
| theflyonthewall.com: | On The Fly: Mid-Day Wrap | | Stocks on Wall Street were lower at mid-day, with the weakness attributed to concern over the failure for Greece and "the troika" to agree on terms of a budget that will trigger additional bailout funds for the troubled nation. The averages have moved in a very narrow range since the open, as investors await news out of Europe. There has been little in the way of U.S. economic news as the market digests its gains from Friday, following the better than expected monthly jobs report... ECONOMIC EVENTS: In the U.S., little market moving economic data was released. Europe's markets were lower following another missed deadline by Greece... MARKET NEWS: Shares of Coinstar (CSTR) advanced, while rival Netflix (NFLX) retreated, after Coinstar's Redbox unit and Verizon (VZ) announced that they would form a movie rental joint venture. Also of note, Coinstar reports earnings after today's close... Humana (HUM) reported Q4 earnings and revenue that missed estimates, but did raise its FY12 view. However, even its higher bar does not meet Street expectations... MAJOR MOVERS: Among the notable gainers were O'Charley's (CHUX), which is being purchased by Fidelity National Financial (FNF) for $9.85 per share, and Threshold Pharmaceuticals (THLD), after signing a global agreement with Merck KGaA (MKGAY) to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted drug. Noteworthy losers included Sohu.com (SOHU), after its earnings and revenue beat expectations but its guidance was disappointing, and Changyou.com (CYOU), following a similar report with good news from the previous quarter but cautionary statements about the next one... INDICES: Near noon, the Dow was down 42.61, or 0.33%, to 12,819.62; the Nasdaq was down 7.07, or 0.24%, to 2,898.59; and the S&P 500 was down 2.87, or 0.21%, to 1,342.03. :theflyonthewall.com |
|
|
February 3, 2012
|
| 16:14 EDT | | THLD |
| theflyonthewall.com: | On The Fly: Closing Wrap | | Stock futures were positive ahead of the non-farm payrolls report, but shot higher when the data was much stronger than expected. The unemployment rate dropped to 8.3% from 8.5% and the buyers were off to the races. The market opened sharply higher with the Dow reaching a level that was double its value from its lowest point in 2009, and the Nasdaq hitting its highest point in 11 years. The averages were strong throughout the day but they moved in a fairly narrow range for most of the session. ECONOMIC EVENTS: In the U.S., non-farm payrolls grew by 243K jobs last month, which was above expectations for growth of 140K jobs. The additions, as well as people dropping out of the workforce, lowered the unemployment rate to 8.3% from 8.5%. The ISM non-manufacturing index came in at 56.8, higher than the consensus of 53.2. Factory orders for the month of December increased 1.1%, versus the expected rise of 1.5%. MAJOR MOVERS: Among the biggest gainers were Threshold Pharmaceuticals (THLD) which soared 127% to $2.93 after Merck (MRK) offered to pay $525M for the right to jointly develop a cancer drug, and Zoltek Cos. (ZOLT) which rallied 39% to $13.16 after sharply beating Q1 EPS estimates. The losers included PC Connection (PCCC) which tumbled 19% to $10.26 after widely missing Q4 PES estimates, and Smart Technologies (SMT) which fell 12% to $3.64 after cutting its full-year forecast. INDICES: The Dow rose 156.82 to 12,862.23, the S&P gained 19.36 to 1,344.90, and the Nasdaq added 45.98 to 2,905.66. :theflyonthewall.com |
| | 12:00 EDT |  | THLD |
| | 10:00 EDT | | THLD |
| theflyonthewall.com: | Threshold Pharma rises 78.3% | | Threshold Pharma is up 78.3%, or $1.01, to $2.30 :theflyonthewall.com |
| | 09:00 EDT | | THLD |
| | 05:41 EDT |  | THLD |
| theflyonthewall.com: | Threshold Pharma and Merck KGaA announce global agreement for TH-302 | | Threshold Pharmaceuticals announced that a global agreement was signed with Merck KGaA, Darmstadt, Germany, to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted drug. TH-302 is currently being investigated in a global Phase 3 clinical trial in patients with soft tissue sarcoma, a randomized Phase 2 trial in patients with advanced pancreatic cancer from which top-line results are expected in February, as well as additional clinical studies in other solid tumors and hematological malignancies. Merck will receive co-development rights, exclusive global commercialization rights and will provide Threshold an option to co-commercialize the therapeutic in the U.S. In exchange, Threshold will receive an upfront payment of $25M and could receive up to $35M in additional development milestones during 2012. Threshold is also eligible to receive a $20M milestone payment based on positive results from its randomized Phase 2 trial in pancreatic cancer. Total potential milestone payments are $525M, comprised of $280M in regulatory and development milestones and $245M in sales-based milestones. In the U.S., Threshold will have primary responsibility for development of TH-302 in the soft tissue sarcoma indication. Threshold and Merck KGaA will jointly develop TH-302 in all other cancer indications being pursued. Merck KGaA will pay 70% of worldwide development costs for TH-302. :theflyonthewall.com |
|
|
|
Subscribe for More Information